As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of CollPlant Biotechnologies Ltd. The largest reported stake is Loewenbaum Lilian S.'s, at 17.5%. 9 filings are on record since September 30, 2025 (Schedule 13D/A, August 21, 2026).
Sell to companies like CollPlant Biotechnologies Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Ami Sagy · Sole voting: 163,709 · Shared voting: 0 · Sole dispositive: 163,709 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-08
- · Holder: Ami Sagy · Percent: 5.7% · SCHEDULE 13D/A
- · Reporting person: Loewenbaum Lilian S. · Sole voting: 186,289 · Shared voting: 0 · Sole dispositive: 186,289 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-21
- · Holder: Loewenbaum Lilian S. · Percent: 25% · SCHEDULE 13D/A
- · Holder: Loewenbaum Lilian S. · Percent: 10.2% · SCHEDULE 13D/A
CollPlant Biotechnologies Ltd. has 9 Schedule 13D or 13G filings on record since 2025-09-30. 2 holders' latest filing reports 5% or more of ordinary shares, no par value (including ordinary shares represented by american depositary shares at a 1-to-1 ratio). Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 Loewenbaum Lilian S.
On October 20, 2025, the Reporting Persons delivered a letter to the Board of Directors of the Issuer (the "Board") requesting the appointment of Nachum Shamir as Chairman in the immediate future and requesting consideration of adding other qualified individuals to the board.From Item 4 of the SCHEDULE 13D/A filed 2025-11-07
Intent stated in Item 4 Loewenbaum Lilian S.
On October 20, 2024, the Reporting Persons delivered a letter to the Board of Directors of the Issuer (the "Board") requesting the appointment of Nachum Shamir as Chairman in the immediate future and requesting consideration of adding other qualified individuals to the board.From Item 4 of the SCHEDULE 13D/A filed 2025-10-20
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 17.5% | 186,289 | SCHEDULE 13D/A, 2026-08-21 | 2026-08-19 | |
| 5.7% | 163,709 | SCHEDULE 13G, 2026-10-08 | 2026-09-30 |
Holding shares or following this stake? See who's behind CollPlant Biotechnologies Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on CollPlant Biotechnologies Ltd. and the records around it.
CollPlant Biotechnologies Ltd. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Form D filing Jul 2026
- Who owns it
Watch CollPlant Biotechnologies Ltd.
Get an email when CollPlant Biotechnologies Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CollPlant Biotechnologies Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CollPlant Biotechnologies Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CollPlant Biotechnologies Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Loewenbaum Lilian S. | 186,289 | 0 | 186,289 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| George Walter Loewenbaum | 1,271,056 | 0 | 1,271,056 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| Elizabeth S. Loewenbaum | 20,688 | 0 | 20,688 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| The Loewenbaum 1992 Trust | 3,597,047 | 0 | 3,597,047 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| The Waterproof Partnership, Ltd. | 35,500 | 0 | 35,500 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| The Loewenbaum Residence Trust FBO Anna Loewenbaum | 15,000 | 0 | 15,000 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| The Elizabeth Scott Loewenbaum 1992 Trust | 15,000 | 0 | 15,000 | 0 | SCHEDULE 13D/A, 2026-08-21 |
| Ami Sagy | 163,709 | 0 | 163,709 | 0 | SCHEDULE 13G, 2026-10-08 |
The latest filing identifies CollPlant Biotechnologies Ltd. by CUSIP M2R51X124 and gives its principal executive office as 4 Oppenheimer Street, Weizmann Science Park, Rehovot (SCHEDULE 13G, 2026-10-08).
Source of funds (Item 3)
The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.Loewenbaum Lilian S., SCHEDULE 13D/A, 2026-08-21
Purpose of Transaction (Item 4)
Loewenbaum Lilian S.
On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-21; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-30 | Loewenbaum Lilian S. | 9.9% | SCHEDULE 13D |
| 2025-10-20 | Loewenbaum Lilian S. intent stated | 9.9% | SCHEDULE 13D/A |
| 2025-11-07 | Loewenbaum Lilian S. intent stated | 9.9% | SCHEDULE 13D/A |
| 2025-11-28 | Ami Sagy | 12.9% | SCHEDULE 13D/A |
| 2026-07-27 | Loewenbaum Lilian S. | 10.2% | SCHEDULE 13D/A |
| 2026-07-31 | Loewenbaum Lilian S. | 25% | SCHEDULE 13D/A |
| 2026-08-21 | Loewenbaum Lilian S. | 17.5% | SCHEDULE 13D/A |
| 2026-10-08 | Ami Sagy | 5.7% | SCHEDULE 13D/A |
| 2026-10-08 | Ami Sagy | 5.7% | SCHEDULE 13G |
Questions about who owns CollPlant Biotechnologies Ltd.
Who owns CollPlant Biotechnologies Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of CollPlant Biotechnologies Ltd.: Loewenbaum Lilian S. (17.5%, Schedule 13D/A, filed 2026-08-21) and Ami Sagy (5.7%, Schedule 13G, filed 2026-10-08).
Who are the largest shareholders of CollPlant Biotechnologies Ltd.?
By the share each holder's latest filing reports, the largest holders of CollPlant Biotechnologies Ltd. on this page are Loewenbaum Lilian S. (17.5%) and Ami Sagy (5.7%).
When did Loewenbaum Lilian S. buy into CollPlant Biotechnologies Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Loewenbaum Lilian S. on this page is the Schedule 13D, filed 2025-09-30, reporting 9.9%; its latest, Schedule 13D/A filed 2026-08-21, reports 17.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for CollPlant Biotechnologies Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 22, 2026 | Form D, private offering | $9.25M sold | Form D page | Source |
| July 20, 2026 | Form D, private offering | $10.40M sold | Form D page | Source |
| February 17, 2026 | Form D, private offering | $4M sold | Form D page | Source |
| June 4, 2025 | Form D, private offering | $3.87M sold | Form D page | Source |
CollPlant Biotechnologies Ltd.: every filing and event
Tools for this story
Each opens in a new tab, filled in for CollPlant Biotechnologies Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.